Product News

Share this article:

GlaxoSmithKline agreed to sell US commercial rights for Wellbutrin XL, an antidepressant, to Biovail Corp. for $510 million, according to a Bloomberg report. Wellbutrin's patent expired over two years ago. GSK will retain rights to the drug outside the US.

 

Rockville, MD-based biotech Vanda Pharmaceuticals secured an FDA approval for its first product, a schizophrenia treatment called Fanapt (iloperidone). The drug will be available in pharmacies later this year, according to a company statement.  

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.